These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21762333)

  • 1. Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids.
    Domingo C; Moreno A; Mirapeix R
    Intern Med J; 2011 Jul; 41(7):525-36. PubMed ID: 21762333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
    Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of omalizumab in non-allergic severe asthma.
    Domingo C; Pomares X; Angril N; Rudi N; Amengual MJ; Mirapeix RM
    J Biol Regul Homeost Agents; 2013; 27(1):45-53. PubMed ID: 23489686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Latin-American Consensus on Difficult-to-Control Asthma. 2008 Update].
    Drugs Today (Barc); 2008 Jun; 44 Suppl 3():1-43. PubMed ID: 19093041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
    J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab in the treatment of asthma.
    Tan R; Corren J
    Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation.
    Sullivan PW; Campbell JD; Ghushchyan VH; Globe G; Lange J; Woolley JM
    J Asthma; 2015 Sep; 52(7):669-80. PubMed ID: 25731600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral corticosteroid-dependent asthma: a 30-year review.
    Randhawa I; Klaustermeyer WB
    Ann Allergy Asthma Immunol; 2007 Oct; 99(4):291-302; quiz 302-3, 370. PubMed ID: 17941275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with omalizumab in a Portuguese severe asthma unit.
    Alfarroba S; Videira W; Galvão-Lucas C; Carvalho F; Bárbara C
    Rev Port Pneumol; 2014; 20(2):78-83. PubMed ID: 24525397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes before and after treatment escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma.
    Sullivan PW; Campbell JD; Ghushchyan VH; Globe G
    Ann Allergy Asthma Immunol; 2015 Jun; 114(6):462-9. PubMed ID: 25890451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study.
    Sthoeger ZM; Eliraz A; Asher I; Berkman N; Elbirt D
    Isr Med Assoc J; 2007 Jun; 9(6):472-5. PubMed ID: 17642399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The add-on effect of omalizumab on patients with uncontrolled bronchial asthma].
    Minami Y; Endo S; Okumur S; Sasaki T; Yamamoto Y; Ogasa T; Osanai S; Ohsaki Y
    Nihon Kokyuki Gakkai Zasshi; 2011 Nov; 49(11):793-9. PubMed ID: 22171481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory and biologic therapies for severe refractory asthma.
    Polosa R; Morjaria J
    Respir Med; 2008 Nov; 102(11):1499-510. PubMed ID: 19012848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.
    Rottem M
    J Asthma; 2012 Feb; 49(1):78-82. PubMed ID: 22149205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients.
    Domingo C; Moreno A; José Amengual M; Montón C; Suárez D; Pomares X
    Curr Med Res Opin; 2011 Jan; 27(1):45-53. PubMed ID: 21083517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.